Anticipate generic drug launch
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Abstract:||1,2,3,4,5,6-Hexahydro-3-lower alkenyl-6-(R.sup.1)-11-(R.sup.2)-8-hydroxy-2,6-methano-3-benzazocines, wherein R.sup.1 and R.sup.2 are hydrogen or lower alkyl, and certain ethers and esters thereof, are obtained from analogous 3-unsubstituted compounds. The products have pharmacodynamic activity and are useful as antagonists of strong analgesic agents, such as morphine and meperidine, and are useful in humans as agents for producing analgesia.|
|Inventor(s):||Archer; Sydney (Bethlehem, NY)|
|Assignee:||Sterling Drug Inc. (New York, NY)|
Patent Claim Types:|
see list of patent claims
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Austria||246157||<disabled in preview>|
|Austria||252248||<disabled in preview>|
|Belgium||611000||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.